The selective targeting of mutant PI3Kα was further shown by differential effects of STX-478 on pAKT/AKT suppression in tumor and muscle, and by assessing glucose oxidation in these tissues with an isotope-labeled glucose OGTT. This evidence concerns the gene AKT1 and neoplasm.